Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for menâ€™s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patientâ€™s regular Prostate-Specific Antigen (PSA) test.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Delayed Börse Stuttgart Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		+2,227.27%	+1,349.60%

05-19	Onconetix, Inc. announces 1-for-10 reverse stock split	RE
05-19	Realbotix provides update on Nasdaq listing	RE

Market Cap	3.99M 3.5M 3.22M 3M 5.66M 379M 5.78M 38.75M 15.01M 186M 14.97M 14.65M 648M	P/E 2024 *	-	P/E 2025	-0.09x
Enterprise Value	-1.19M -1.04M -958K -892K -1.68M -113M -1.72M -11.52M -4.46M -55.3M -4.45M -4.35M -192M	EV / Sales 2024	5,556,319x	EV / Sales 2025	-3,367,890x
Free-Float	99.81%	Yield 2024 *	-	Yield 2025	-

05-19	Onconetix, Inc. announces 1-for-10 reverse stock split	RE
05-19	Realbotix provides update on Nasdaq listing	RE
05-13	Onconetix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-25	Onconetix Inc Andrew Oakley resigns as chairman of board	RE
04-25	Onconetix, Inc. Announces Board and Committee Changes	CI
03-31	Onconetix appoints David White as chief executive officer and Sammy Dorf as member of the board of directors	RE
03-25	Onconetix on March 18 appointed David White as CEO, effective as of that date	RE
03-25	Onconetix, Inc. Announces Chief Executive Officer Changes, Effective March 18, 2026	CI
03-25	Onconetix, Inc. Announces Board and Committee Changes, Effective as of March 19, 2026	CI
03-23	Onconetix, Inc. announces 1-for-5 reverse stock split	RE
03-14	Onconetix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-13	Onconetix, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-14	Onconetix, Inc., Realbotix Corp. - M&A Call

13/09/23	Maxim Downgrades Blue Water Biotech to Hold From Buy	MT
26/04/23	HC Wainwright Adjusts Price Target on Blue Water Biotech to $9 From $7, Maintains Buy Rating	MT
08/12/22	Maxim Starts Blue Water Vaccines at Buy With $4 Price Target	MT

Onconetix, Inc. Stock Börse Stuttgart

Stocks

J4T0

US68237Q1040

Pharmaceuticals

Valuation: Onconetix, Inc.

Latest news : Onconetix, Inc.

Last Transcript: Onconetix, Inc.

Analysts' recommendations: Onconetix, Inc.

Press Releases: Onconetix, Inc.

News in other languages: Onconetix, Inc.

Managers and Directors: Onconetix, Inc.

Biopharmaceuticals

Financials

Company Profile

Income Statement and Estimates

06-24	Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District	AQ
05-19	Onconetix, Inc. Announces 1-for-10 Reverse Stock Split	AQ
05-13	Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study	AQ
04-09	Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson	AQ
04-02	Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update	AQ

Manager	Title	Age	Since
David White CEO	Chief Executive Officer	73	18/03/2026
Karina Fedasz CEO	Chief Executive Officer	53	02/04/2025

Director	Title	Age	Since
Simon Tarsh BRD	Director/Board Member	64	01/08/2022
Sarah Romano BRD	Director/Board Member	46	05/12/2025
Sammy Dorf CHM	Chairman	41	23/04/2026

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCONETIX, INC.	-.--%	+2,227.27%	-	-	3.99M
REGENERON PHARMACEUTICALS, INC.	+0.19%	+0.21%	+16.79%	-13.06%	63.56B
UCB	-1.56%	+1.14%	+54.57%	+217.61%	55.92B
SAMSUNG BIOLOGICS CO.,LTD.	+0.36%	+39.60%	+39.60%	+39.60%	41.68B
CSL LIMITED	-0.44%	+0.18%	-50.84%	-57.34%	39.12B
BIOGEN INC.	-2.93%	+5.09%	+61.25%	-26.37%	30.97B
MODERNA, INC.	+3.53%	+19.99%	+152.70%	-40.33%	28.77B
INCYTE CORPORATION	+0.40%	+4.93%	+65.59%	+82.83%	22.74B
INNOVENT BIOLOGICS, INC.	+7.16%	+12.02%	+7.50%	+184.17%	17.64B
SWEDISH ORPHAN BIOVITRUM AB	+1.34%	-0.64%	+64.17%	+122.53%	16.66B
Average	+0.80%	+4.68%	+45.70%	+56.63%	35.23B
Weighted average by Cap.	+0.29%	+3.82%	+40.25%	+50.28%

	2024	2025
Net sales	2.52 2.22 2.04 1.9 3.58 239.97 3.66 24.53 9.51 117.79 9.48 9.27 409.95	0.82 0.72 0.66 0.61 1.16 77.52 1.18 7.93 3.07 38.05 3.06 3 132.43
Net income	-58.69M -51.53M -47.43M -44.2M -83.36M -5.58B -85.05M -570M -221M -2.74B -220M -216M -9.53B	-14.03M -12.32M -11.34M -10.57M -19.93M -1.33B -20.33M -136M -52.85M -655M -52.69M -51.55M -2.28B
Net Debt	8.8M 7.73M 7.11M 6.63M 12.5M 837M 12.75M 85.55M 33.15M 411M 33.05M 32.33M 1.43B	-5.17M -4.54M -4.18M -3.89M -7.35M -492M -7.49M -50.27M -19.48M -241M -19.42M -19M -840M